ZADH2

Across TCGA pan-cancer cohorts, ZADH2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZADH2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZADH2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZADH2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where ZADH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.939	0.637	<.001	52	view →
PDAC	DFS	Quartile	II,III,IV	0.548	0.280	.002	49	view →
UCEC	OS	Tertile	II,III,IV	0.380	1.000	.010	24	view →
COAD	DFS	Median	III,IV	1.000	0.838	.036	6	view →
HNSC	DFS	Median	III,IV	0.712	0.527	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZADH2–CCRCC (OS)

Open the CCRCC breakdown →